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Polymorphonuclear leukocyte (PMN) and mononu-
clear cell (MNC) locomotion was investigated in patients 
with psoriasis vulgaris before and after treatment with 
oral photochemotherapy (PUV A) and was found to be 
significantly increased (PMN: p < 0.001; MNC: p < 0.002) 
when compared to healthy controls. No significant dif-
ference was observed in the locomotion of PMN or MNC 
before and after PUV A treatment. These results indicate 
that PMN and MNC locomotion is increased in psoriasis 
vulgaris and remains unaltered by PUV A treatment. 
Psoriatic plaques contain increased amounts of a complement 
dependent chemotactic factor which might be responsible for 
the accumulation of polymorphonuclear leukocytes (PMN) in 
psoriatic skin lesions [1]. Wahba et al [2] demonstrated an 
enhanced chemotactic response of circulating PMN obtained 
from untreated patients with psoriasis. In contrast Krueger, 
Hill, and Jederberg failed to demonstrate increased locomotion 
activity of PMN [3] in psoriasis but reported an increased 
chemotactic response of circulating mononuclear cells (MNC) 
[ 4]. 
This study was performed in order to investigate whether 
photochemotherapy (PUV A) [5] affects the locomotion ability 
of circulating MNC and PMN in psoriatic patients. 
MATERIALS AND METHODS 
Subjects 
A total of 98 individuals was studied, 44 patients with psonas1s 
vulgaris (stable plaque type) and 54 healthy volunteers. ALL of the 
psoriatic patients were untreated for at least 30 days prior to the 
investigations and had 30 to 50% of the body surface involved. 
Mononuclear cell (MNC) locomotion was studied in a total of 21 
psoriatic patients, 7 females (f) , 14 males (m), age: 37.4 ± 4.1 years (yr;) 
mean (x) ± standard error of the mean (SEM) prior to the treatment. 
Ten patients out of this group (5 m, 5 f; x age 38.1 ± 3.94 yr) were also 
investigated after complete clearing by oral photochemotherapy 
(PUVA); total UVA dose delivered: 64.2 ± 12.4 Joules/cm2 25 healthy 
age- and sex-matched volunteers served as controls. Polymorphonu-
clear leucocyte (PMN) locomotion was determined in an identical set 
up in the remaining 23 psoriatic patients, 10 f, 13m; x age: 40.7 ± 13.7 
yr; in 12 patients out of this group, 7 f, 5 m; x age 29.5 ± 4.2 yr before 
PUV A and after PUVA clearing phase (total UV A dose: 72.9 ± 9.9 
Joules/cm2 ) and in 29 healthy volunteers. Photochemotherapy (PUVA) 
was performed using a PUVA 4000 irradiation unit (Waldmann, 
Schwenningen, Germany). After phototesting [6] patients were treated 
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Ll: Locomotion index 
MNC: Mononuclear cell 
PMN: polymorphonuclear leukocyte 
187 
aggressively 4 times per week. Treatment resulted in rapid clearing of 
the skin lesions accompanied by 1 + to 2+ erythematous reactions. 
There was an interval of at least 24 hl" between the last PUV A exposul"e 
and the locomotion assays. 
LOCOMOTION ASSAY 
MNC were isolated from heparinized venous blood by Ficoll 
Hypaque separation [7] and PMN were gained by sedimenta-
tion of heparinized venous blood with 2% Dextran 500 (Phar-
macia, Uppsala, Sweden) [8). Contaminating erythrocytes were 
lysed by 0.84% NR,Cl; cells were washed 3 times in medium 
RPMI 1640 (Flow Laboratories, Bonn, Gemany) containing 100 
IU penicillin per rnl, 100 p.g streptomycin (Gibco, Glasgow, 
Scotland) per rnl, 2% bovine serum albumin (Fluka, Buchs, 
Switzerland) and were then adjusted in medium to a concen-
tration of 2 X 106 cells/rnl. T:rypan blue exclusion revealed more 
than 94% viable cells, in all experiments. 
Locomotion was determined by a modification [9] of Boy-
den's [10] miCI"opore ftlter technique. 0.5 m1 of cell suspensions 
were placed in the upper compartment ofthe chemotaxis cham-
ber; 1.5 m1 of a pooled normal human serum, activated by 
incubation with zymosan (Koch Light Laboratories Colnbrook, 
Bucks UK) and diluted in gelatine verona! buffered saline 
(pH7.3) according to Clark and Kelbanoff [11], served as cyto-
taxin in the lower compartment. Filters, 5 p.m and 3 p.m pore 
size (Millipore Corporation, Bedford, Massachusetts, USA), 
were used for the determination ofMNC and PMN locomotion, 
respectively. After incubation for 120 min at 37°C, filters were 
detached, stained with hemalwn and the cells present on the 
lower side of the filters were counted in 20 oil immersion fields. 
Assays were performed in triplicate and the results were ex-
pressed as locomotion index (Ll) = mean number of cells<iJ 
immersion field ± SEM. The random mobility of the cells was 
evaluated by determining the L1 using gelatine verona! buffered 
saline (without the cytotaxin)-in the lower compartment of the 
chemotaxis chamber. 
Statistical analysis was performed by the Student's t-test. 
RESULTS 
The results are listed in detail in the Table. The mean LI of 
MNC as well as PMN was significantly higher: (MNC: p < 
0.002; PMN: p < 0.001) in patients with psoriasis when com-
pared to the mean LI of the healthy controls. No significant 
difference was observed in the Ll of MNC or PMN in psoriatic 
patients when determined before PUV A treatment and after 
complete clearing by PUVA (p > 0.2). The random mobility of 
MNC and PMN respectively was not statistically different (p 
> 0.2) when compared in patients versus controls, and in 
patients before and after PUVA treatment. 
DISCUSSION 
The significant increase in the response of psoriatic PMN to 
zymosan activated serum as chemoattractant in this study 
supports the finding of Wahba et al [2] and indicates that both 
an increased susceptibility of circulating PMN to chemoattrac-
tants in psoriasis plus an increased amount of chemotactic 
factors produced in psoriatic epidermis, as reported recently 
[1], are responsible for the presence ofPMN in psoriatic stratum 
corneum. In contrast to Wahba et al and also in contrast to this 
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Locomotion indices 
Normal individuals Psoriatic patients 
Without treatment Before PUVA After PUV A clearing 
N ZAS RM 
N ZAS RM N ZAS RM ZAS RM 
PMN 29 3.3 ± 0.2 0.6 ± 0.1 23 7.3 ± 0.7 0.9 ± 0.1 12 7.2 ± 0.8 0.7 ± 0.1 6.4 ± 0.7 0.6 ± 0.1 
MNC 25 3.5 ± 0.2 1.2 ± 0.2 21 5.2 ± 0.4 1.1 ± 0.1 10 5.3 ± 1.1 0.9 ± 0.2 4.3 ± 0.4 0.7 ± 0.1 
N = number (of individuals). 
PMN = polymorphonuclear cells (leukocytes) . 
MNC = mononuclear cells. 
ZAS = zymosan activated serum (cytotaxin). 
RM =random mobility. 
study, Krueger et al [3] were unable to demonstrate an in-
creased PMN locomotion ability in psoriasis. Obviously these 
differences remain to be clarified although they might be ex-
plained by the slightly different experimental approaches em-
ployed. 
8-methoxypsoralen plus long-wave ultraviolet (UV A) radia-
tion as used in photochemotherapy (PUV A) has been shown to 
influence both MNC [12] and PMN in vitro [13] as well as in 
vivo in some patients [14]. Although the present study supports 
previous findings of an increased MNC locomotion ability in 
untreated psoriasis it failed to show significant differences in 
the locomotion ability of PMN and MNC in psoriatic patients 
before and after clearing of the skin lesions by intensive 4 times 
per week PUV A treatment leading to a 1 + 2 + erythema. This 
indicates that PUV A may not influence circulating PMN and 
MNC in vivo, at least as locomotion ability is concerned. Since 
PUV A treatment leads to a rapid clearing of psoriatic skin 
lesions including early disappearance of PMN foci both in 
psoriasis vulgaris [5] and pustular psoriasis (Zumbusch) [15], 
one could hypothesize that PUV A may stop the accumulation 
of PMN in psoriatic epidermis rather by an effect in epidermal 
production of chemoattractants [16] than by a direct influence 
of the circulating polymorphonuclear cells. 
REFERENCES 
1. Lazarus GS, Yost FS, Thomas ChA: Polymorphonucleru· leuko-
cytes: Possible mechanism of accumulation in psoriasis. Science 
198:1161-1163, 1977 
2. Wahba A, Cohen HA, Bar-Eli M, Gallily R: Enhanced chemotactic 
phagocytic activities of leukocytes in psoriasis vulgaris. J Invest 
Dermatol 71:186-188, 1978 
3. Krueger GG, Hill HR, Jederberg WW: Inflammatory and immune 
cell function in psoriasis-A subtle disorder. I. In vivo and in 
vitro survey. J Invest Dermatol 71:189-194, 1978 
4. Krueger GG, Jederberg WW, Ogden BE, Reese DL: Inflammatory 
and immune cell function in psoriasis: II. Monocyte function, 
lymphokine production. J Invest Dermatol 71:195-201, 1978 
5. Wolff K, Fitzpatrick TB, Parrish JA, Gschnait F, Gilchrest B, 
Honigsmann H, Pathak MA, Tanenbaum L: Photochemotherapy 
for psoriasis with orally administered methoxalen. Arch Derma-
to! 112:943-950, 1976 
6. Wolff K, Gschnait F, Honigsmann H, Konrad K, Panish JA, 
Fitzpatrick TP: Phototesting and dosimetry for photochemo-
therapy. Br J Dermatol 96:1-10, 1977 
7. Nelson DL, Bundy BM, Pitchon HE, Blaese RM, Strober W: The 
effector cells in huma n peripheral blood mediating mitogen-in-
duced cellular cytotoxicity and antibody-dependent cellulru· cy-
totoxicity. J Immunol 117:1472-81, 1976 
8. Zielinski Ch, Pehamberger H, Endler T, Knapp W: Serum associ-
ated chemotaxis inhibition and leukocyte chemotaxis in malig-
nant melanoma. Effect of BCG treatment. Clin Exper Immunol 
38:92-98, 1979 
9. Frei PC, Baisero MH, Ochsner M: Chemotaxis of human polymor-
phonuclears in vitro. J Immunol Methods 6:375-382, 1974 
10. Boyden S: The chemotactic effect of mixtu1·es of antibody and 
antigen on polymorphonucleru· leukocytes. J Exp Med 115:453-
462, 1962 
11. Clark RA, Klebanoff SJ: Role of the classical and alternative 
complement pathways in chemotaxis and opsonisation: studies 
of human serum deficient in C.,. J Immunol 120:1102-1110, 1975 
12. Kruger SP, Christophers E, Schlaak M: Dose effects of 8-methox-
ypsoralen and UV A in cultured human lymphocytes. Br J Der-
matol 98:141-144, 1978 
13. Langner A, Christophers E: Leukocyte chemotaxis after in vitro 
treatment with 8-methoxypsoralen and UV A. Arch Derma to! 
Res 260:51-55, 1977 
14. Kraemer KH, Weinstein GD: Decreased thymidine incorporation 
in circulating leukocytes after treatment of psoriasis with psora-
len and long wave ultraviolet light. J Invest Derrnatol 69:211-
214, 1977 
15. Honigsmann H , Gschnait F, Konrad K, Wolfl' K: Photocherno-
therapy for pustular psoriasis (von Zumbusch). Br J Dermatol 
97:119-126, 1977 
16. Mizunon, Enami H, Esaki K: Effect of 8-methoxypsoralen plus 
UV A on psoriasis leukotactic factor. J Invest Dermatol 72:64-66, 
1979 
